Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Research

| More

ICICI Lombard General Insurance Company - Cyclical recovery can protract; fundamentals remain intact - ICICI Securities

Posted On: 2021-04-19 03:11:22 (Time Zone: UTC)


We expect ICICI Lombard's (ICICIGI) health product / channel mix to be reoriented as its principal bancassurance partner (ICICI Bank) reduces it focus on sale of credit-linked attachment products. Near-term challenges for ICICIGI include: 1) sustained competitive intensity and higher claims in motor OD, and 2) delay in motor TP price hike. However, with emphasis on retail sales, new partnerships and new products amid strong demand and favourable base, we expect ICICIGI's health segment growth to recover in FY22E/FY23E. Revival of premium growth in motor segment and possible price hikes in motor TP remain positive triggers. Maintain ADD with a target price of Rs1,584, implying 37x FY22E EPS of ~Rs42.4.

- Rs15bn PAT in FY21 was in-line; we expect Rs19.3bn PAT in FY23E. We estimate Rs19.3bn PAT in FY23E on the back of: 1) the 11.6% / 8.1% NEP growth in FY22E / FY23E, 2) 71% / 72.8% loss ratio in FY22 / FY23E, 3) 29.6% / 26.8% opex ratio (commission plus expenses) in FY22E / FY23E, and 4) Rs24.6bn / Rs29.4bn investment income in FY22E / FY23E.

- Covid / Non-Covid health, lower frequency / higher severity in motor claims, and recovery in motor segment growth will determine FY22 profitability. Lower motor claims (Rs39bn in FY21 vs Rs47bn in FY20) and moderate rise in health claims (Rs17bn in FY21 vs Rs15.8bn in FY20) were positive for ICICIGI in FY21 despite lower NEP growth (+6.5%). Motor / Health loss ratios stood at 66% / 77% in FY21 vs 77% / 70% in FY20. It remains to be seen how the combination plays out again in FY22 with possible demand recovery in motor and higher pricing as the likely positive triggers. ICICIGI received total covid claims of Rs3.76bn in FY21 (2.6% of total industry claims).

- Strong execution & robust balance sheet can be long-term tailwinds. ICICIGI has managed strong organic expansion with the number of agents increasing from 35,729 in FY19 to 59,545 in FY21 and virtual offices from 135 in FY18 to 840 in Q4FY21. Company has also embarked on inorganic growth with the acquisition of Bharti Axa, which had 1.6% GDPI market share in FY21. It also acquired AutoNinja (CRM software for auto dealers) in Nov'19, which has helped renewal rate in motor insurance). 'IL Take Care' app for customer engagement & servicing of health, motor and travel customer saw more than 500K+ downloads till FY21 (450K+ downloads in FY21) The superior execution track record will be further aided by strong balance sheet with solvency of 2.9x as of FY21 and an AUM including fair value change amount of Rs308bn (equity exposure stood at ~12.5% in FY21; up from 9.8% in Q1FY21, 10.2% in H1FY21 and 10.9% in 9MFY21).

- Second Covid wave can delay cyclical recovery; maintain ADD. We had expected a cyclical recovery in FY22E for well-entrenched general insurers like ICICIGI, but the second wave of Covid can cause delay. However, a market leader like ICICIGI is well placed to cope with it. We maintain ADD on the stock with a target price of Rs1,584, implying 37x FY22E EPS of ~Rs42.4

Shares of ICICI Lombard General Insurance Company Ltd was last trading in BSE at Rs.1423 as compared to the previous close of Rs. 1388.05. The total number of shares traded during the day was 18587 in over 2015 trades.

The stock hit an intraday high of Rs. 1426.95 and intraday low of 1385. The net turnover during the day was Rs. 26237334.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.


Other Headlines:

Cadila Healthcare - Divests animal health business - ICICI Securities

Q4FY21 Result Update - Granules India - ICICI Direct

Q4FY21 Company Update - Firstsource Solutions - ICICI Direct

Q4FY21 Company Update - Sonata Software - ICICI Direct

Company Update - Cadila Healthcare - ICICI Direct

Q4FY21 Result Update - Kalpataru Power - ICICI Direct

Q4FY21 Result Update - KEC International - ICICI Direct

Q4FY21 Company Update - Matrimony.com Ltd - ICICI Direct

Maintain REDUCE on Asian Paints - Exceeds expectations - HDFC Securities

JMC Projects Results Report - Poised for growth - HDFC Securities

Maintain ADD on Godrej Consumers - Miss in 4Q margin; inspiring addition to team - HDFC Securities

Maintain BUY on Birla Corporation - Healthy performance - HDFC Securities

Subscriber watch - Bharti wins more market share across categories - ICICI Securities

Siemens Ltd - Healthy margins with growth recovery - ICICI Securities

Godrej Consumer Products - Jigsaw falling in place; retain top pick status - ICICI Securities

Thyrocare Technologies - Margins subdued despite growth recovery - ICICI Securities

Q4FY21 Result Update - Zydus Wellness - ICICI Direct

Q4FY21 Result Update - EIH Ltd - ICICI Direct

Q4FY21 Company Update - Intellect Design Arena - ICICI Direct

Q2FY21 Company Update - Siemens Ltd - ICICI Direct

UltraTech Cement - In-line strong performance; Capex plan retained - HDFC Securities

April AMFI Data - Mr. Aashish P Somaiyaa, Chief Executive Officer - White Oak Capital

Maintain ADD on Navin Fluorine International - High-value business aids growth - HDFC Securities

Maintain BUY on Kansai Nerolac - Raw material cost pressure palpable - HDFC Securities

Cholamandalam Investment and Finance Company - A steady quarter - HDFC Securities

Grindwell Norton - Moving towards a new orbit - ICICI Securities

Kansai Nerolac Paints - Another (margin) miss story; not unexpected though - ICICI Securities

UltraTech Cement - 2nd covid wave a blip; long-term thesis intact - ICICI Securities

Zydus Wellness - Symphony; retain top pick status - ICICI Securities

Cholamandalam Investment and Finance - Beefing-up buffer to cushion earnings; positioned to grow when normalcy returns - ICICI Securities

Navin Fluorine International - Demanding valuation caps upside - ICICI Securities

Q4FY21 Result Update - Dabur India - ICICI Direct

Q4FY21 Result Update - Tata Consumer Products - ICICI Direct

Q4FY21 Result Update - DCB Bank - ICICI Direct

Q4FY21 Result Update - Navin Fluorine - ICICI Direct

Q4FY21 Result Update - UltraTech Cement - ICICI Direct

Q4FY21 Result Update - Kansai Nerolac Paints - ICICI Direct

Q4FY21 Result Update - IDFC First Bank - ICICI Direct

Q4FY21 Result Update - Grindwell Norton - ICICI Direct

Cholamandalam Invest. & Finance - Q4FY21 Result Update - YES Securities

Ultratech Cement Ltd - Q4FY21 Result Update - YES Securities

JMC Projects (India) - Q4 FY21 first cut - Robust Performance - YES Securities

Brokerage Views on DCB Bank's Q4FY21 results

Maintain ADD on Dabur - Exciting FY21; miss in 4Q margin - HDFC Securities

Deepak Nitrite Results Review - Decent performance - HDFC Securities

Maintain ADD on DCB Bank - Lower provisions drive beat in earnings - HDFC Securities

Bandhan Bank Report - Surging micro-credit stress - HDFC Securities

Avenue Supermarts Q4FY21 Results Review - In-line performance; FY22 recovery tapered down - HDFC Securities

Chola Inv. & Fin. - Q4 FY21 first take - 'Strong on growth, in-line on asset quality'

Blue star Ltd - Q4FY21 Result Update - YES Securities


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020